Table 3.
Late effects among 1-year disease-free survivors following second allogeneic hematopoietic cell transplantation
| Patient and transplant characteristics |
Age group at second transplant | |||||
|---|---|---|---|---|---|---|
| Children (≤ 18 years) | Adults (>18 years) | |||||
| Rate prior to 2nd HCT* N (%) |
CI at 2- years† % (95% CI) |
CI at 10- years† % (95% CI) |
Rate prior to 2nd HCT* N (%) |
CI at 2- years† % (95% CI) |
CI at 10- years† % (95% CI) |
|
| Seizure/stroke | 4 (3) | 4 (1–7) | 4 (2–8) | 2 (1) | 0 | 1 (0–2) |
| Myocardial infarction | 0 | 0 | 0 | 0 | 1 (0–2) | 1 (0–2) |
| Gonadal dysfunction | 3 (2) | 6 (3–11) | 16 (10–23) | 9 (5) | 4 (2–7) | 5 (2–8) |
| Renal failure | 1 (1) | 1 (0–4) | 4 (1–8) | 2 (1) | 3 (1–6) | 4 (1–7) |
| Avascular necrosis | 2 (1) | 4 (2–8) | 5 (2–9) | 4 (2) | 10 (6–15) | 13 (9–19) |
| Cataracts | 1 (1) | 9 (4–14) | 20 (13–28) | 9 (5) | 14 (9–20) | 20 (14–26) |
| Growth hormone deficiency/growth failure | 4 (3) | 8 (4–14) | 22 (15–30) | 0 | 0 | 0 |
| Hypothyroidism | 1 (1) | 7 (3–12) | 13 (7–20) | 2 (1) | 2 (1–5) | 4 (1–7) |
| Cirrhosis | 0 | 0 | 0 | 0 | 0 | 0 |
| Bronchiolitis obliterans | 0 | 3 (1–7) | 4 (1–8) | 1 (1) | 4 (2–8) | 4 (2–8) |
| Second cancers | 0 | 1 (0–3) | 1 (0–4) | 2 (1) | 1 (0–3) | 8 (4–13) |
CI = cumulative incidence
*
Rate of late effects after first allogeneic transplant, but before second transplant (censored at time of second transplantation)
†
Cumulative incidence estimates